Characteristics | Placebo (n = 37) | Rosuvastatin (n = 27) | p value | ||
---|---|---|---|---|---|
Baseline | Follow-up | Baseline | Follow-up | ||
Age, y | 56 ± 13 | 51 ± 11 | 0.17 | ||
Hemodynamics | |||||
HR (bpm) | 70 ± 8 | 70 ± 11 | 70 ± 8 | 68 ± 10 | 0.82 |
SBP (mm Hg) | 130 ± 17 | 131 ± 13 | 131 ± 20 | 132 ± 17 | 0.76 |
DBP (mm Hg) | 77 ± 10 | 77 ± 13 | 76 ± 9 | 74 ± 11 | 0.79 |
Aortic Valve Parameters | |||||
AVA (cm2) | 1.9 ± 0.7 | 1.6 ± 0.7* | 1.9 ± 0.6 | 1.6 ± 0.6† | 0.62 |
AV peak velocity (m/s) | 2.8 ± 0.1 | 3.3 ± 0.7* | 2.7 ± 0.2 | 3.1 ± 0.5† | 0.57 |
AV peak gradient (mm Hg) | 31 ± 3 | 42 ± 11* | 32 ± 3 | 43 ± 12† | 0.60 |
AV mean gradient (mm Hg) | 17 ± 2 | 31 ± 3* | 17 ± 2 | 30 ± 4† | 0.58 |
Left Heart Dimensions | |||||
IVS (mm) | 11 ± 2 | 11 ± 2 | 11 ± 2 | 11 ± 2 | 0.94 |
PWT (mm) | 10 ± 2 | 11 ± 2 | 10 ± 2 | 10 ± 2 | 0.76 |
LA (mm) | 37 ± 6 | 37 ± 6 | 36 ± 6 | 37 ± 7 | 0.78 |
LVEDD (mm) | 49 ± 5 | 49 ± 7 | 49 ± 7 | 49 ± 7 | 0.81 |
LVESD (mm) | 29 ± 4 | 29 ± 7 | 29 ± 6 | 29 ± 6 | 0.84 |
LV mass/BSA (g/m2) | |||||
Men | 95 ± 24 | 93 ± 23 | 94 ± 28 | 95 ± 23 | 0.61 |
Women | 85 ± 19 | 87 ± 25 | 84 ± 24 | 86 ± 19 | 0.69 |
EF (%) | 65 ± 6 | 67 ± 4 | 65 ± 6 | 68 ± 9 | 0.58 |
Conventional Diastolic Parameters | |||||
Mitral E velocity (cm/sec) | 84 ± 19 | 88 ± 23 | 82 ± 20 | 89 ± 21 | 0.59 |
Mitral A velocity (cm/sec) | 74 ± 18 | 76 ± 18 | 73 ± 25 | 75 ± 25 | 0.64 |
E/A ratio | 1.2 ± 0.4 | 1.1 ± 0.3 | 1.1 ± 0.4 | 1.2 ± 0.5 | 0.71 |
Tissue Doppler Imaging | |||||
Lateral S' | 8.4 ± 3.2 | 8.3 ± 1.8 | 8.5 ± 2.3 | 8.4 ± 2.1 | 0.75 |
Lateral E' | 10.2 ± 4.2 | 8.0 ± 3.2* | 10.5 ± 3.5 | 8.2 ± 3.1† | 0.66 |
Lateral A' | 9.2 ± 3.6 | 9.4 ± 2.8 | 9.1 ± 2.4 | 9.4 ± 3.0 | 0.56 |
E/E' (lateral) | 8 ± 4 | 11 ± 3* | 8 ± 3 | 11 ± 4† | 0.43 |